Role of Biomarkers in Chemotherapy-Induced Cardiotoxicity
- 1 September 2010
- journal article
- review article
- Published by Elsevier BV in Progress in Cardiovascular Diseases
- Vol. 53 (2), 121-129
- https://doi.org/10.1016/j.pcad.2010.04.002
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Anthracycline-Induced CardiomyopathyJournal of the American College of Cardiology, 2010
- Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapyZeitschrift für Krebsforschung und Klinische Onkologie, 2008
- Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme InhibitionCirculation, 2006
- Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategiesBritish Journal of Haematology, 2005
- Cardiovascular Complications of Cancer TherapyCell Metabolism, 2004
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary ArticleCirculation, 2003
- Potential protective role of angiotensin‐converting enzyme inhibitors captopril and enalapril against adriamycin‐induced acute cardiac and hepatic toxicity in ratsJournal of Applied Toxicology, 2001
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJournal of the American College of Cardiology, 2000
- Detection of anthracycline-induced cardiotoxicityCancer Treatment Reviews, 1999